All News

Synovitis

Might Synovial Biopsy Predict Rheumatoid Treatment Responses?

EurekAlert!

Multi-modal analysis of rheumatoid arthritis (RA) synovitis pathotypes enables more accurate choices of first line cDMARDs treatment, suggesting a predictive value to synovial biopsy. 

Read Article
RA Hands Difficult deformity

EULAR 2024 – Day 2 Report (A Difficult RA Day)

Jack Cush, MD

Day 2 at EULAR 2024 was a big poster day for many with several good sessions and oral presentations on Preventing RA, new vasculitis therapies and a session devoted to the 50th anniversary of the Moll & Wright Criteria.

Read Article
scale decision balance question

Dual seropositivity and shared epitopes in RA: friends or foes?

Aurelie Najm, MD, PhD

Dual seropositivity (rheumatoid factor and/or anti-citrullinated protein antibodies) as well as shared epitope are known to be associated with poor prognosis and structural damage in RA.

Read Article
syringe

Belimumab’s Sustained Impact in Lupus

Mrinalini Dey, MD

In the wake of the EULAR 2023 guidelines on the management of SLE, it is perhaps pertinent that the EULAR 2024 congress features three abstracts from a large integrated analysis from five international Phase 3 belimumab trials in adults with active SLE (BLISS-76, BLISS-52, North East Asia, EMBRACE and BLISS-SC). Participants were randomised to belimumab (10 mg/kg/month intravenously or 200 mg/week subcutaneously) or placebo, plus standard therapy.

Read Article
Approach to TB screening prior to commencing biologics. Hyrich K #EULAR2024 @RheumNow https://t.co/j3PI0PHpqW

Links:

Dr. Antoni Chan synovialjoints ( View Tweet)
Cycle or swap 2? Post failure to a first TNFi in patients with PsA, there was no difference in cycle versus swap to IL17i for drug retention rate or disease activity. In male PsA patients a cycle strategy had a longer drug retention rate compared to a swap (IL-17i) strategy.… https://t.co/5BykvDwFWV https://t.co/GfcnIltV2A

Links:

Dr. Antoni Chan synovialjoints ( View Tweet)
#EULAR2024 Please find our Day 1 & Day 2 Recap of selective abstracts/research presented at the conference 😃@RheumNow @DrMiniDey https://t.co/AHl18gS7gF https://t.co/LEoa9rBNly

Links:

Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
#EULAR2024 OP0295 Approriate patient stratification matters in trials. H2H RCT of Tocilizumab vs Rituximab in refractory #SSc-ILD (failed CyC), stratified based on RNA-seq of lungs biopsy showed improved efficacy in TCZ with low B-cell lineage expression signature @RheumNow https://t.co/7ME3Bd2PeM

Links:

Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
#EULAR2024 POS0257 One for the future. Phase 2A RCT showed KPG-818, a Novel Cereblon Modulator (targets Aiolos & Ikaros) was well tolerated with efficacy signal (SLEDAI-2K & CLASI-50). Effect and safety profile were numerically better in the lowest dose @RheumNow https://t.co/Bjk9zBRmVo

Links:

Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
Does TCZ switch off GCA histopathologically? GCA pts still on TCZ (median 2.4y duration) had repeat temporal artery biopsy (contralat) Despite serological remission on TCZ, a heap had active histopath findings & PET still active. Scary #EULAR2024 OP0233 Reggio Emilia @RheumNow https://t.co/TKBUP5p4R0

Links:

David Liew drdavidliew ( View Tweet)
Greatest chance of sustained drug-free remission (DFR) is seen in early RA pts, NEVER requiring a biologic (esp if seronegative blue line). ERA on biologics never achieve DFR (yellow). Leiden EAC clinic study of 627 ERA pts Abstr# POS0615 #EULAR2024 https://t.co/zpCG6oSE3T
Dr. John Cush RheumNow ( View Tweet)
lanalumab (anti-baff) LTE 1/3 to 1/2 LLDAS/DORIS remission at 52 wks, reduction autoabs etc - looking very promising @rheumnow #EULAR2024

Peter Nash drpnash ( View Tweet)

Day 1 #EULAR2024 Do you want to learn about the effectiveness of rituximab for systemic features of #Sjogren and potential strategies to overcome non-response? Please come to my talk today (OP0076) and say hi 👋🏼 😃 Room C7 at 1720 hr CET @RheumNow https://t.co/uo2ivC5AeY

Links:

Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
Biosimilar uptake across the world. Interesting that rich countries use more biosimilars - presumably because they have bargaining power - and that means they can access even better pricing. #EULAR2024 POS0597 Leiden @RheumNow https://t.co/wZgA0JH5uu

Links:

David Liew drdavidliew ( View Tweet)
OP0201- clinical characteristics of pts failing ≥2 b/tsDMARDs D2T RA pts characterised by ⏰ Earlier disease ⏰ Later initiation of DMARD therapy Discontinuation of drugs mainly due to inefficacy regardless of number of drug lines or MOAs used #EULAR2024 @RheumNow

Mrinalini Dey DrMiniDey ( View Tweet)

#EULAR2024 OP0008 Phase 2 #Sjogren RCT Iscalimumab, anti-CD40mAb in two cohorts (1=High systemic activity; 2=High symptom burden but low systemic) showed sustained improvement in ESSDAI & ESSPRI at 48wks in ISC-ISC group, as well as those switched at 24wks from PBO-ISC @RheumNow https://t.co/GuifDHA0lK

Links:

Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
#EULAR2024 OP0089 Promising data from Phase 2 RCT on dual blockade depletion & BAFF-R-i, Ianalumab in #lupus. After 24 wks double-blind, sustained response (SRI-4 + Pred ≤5mg/d or ≤ BL dose) was seen in IAN-IAN group while PBO-IAN improved in open label phase at 48wks @RheumNow https://t.co/MUo76ii4vB

Links:

Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
12-week ARGO Phase 2 trial data of IL-17A- and IL-17F-inhibiting Nanobody sonelokimab delivers rapid onset and robust levels of clinical response, including high-threshold outcomes, compared with placebo in patients with active PsA, with a favorable benefit–risk profile. It met… https://t.co/4wj222FkzP https://t.co/ipUSjKvpuB

Links:

Dr. Antoni Chan synovialjoints ( View Tweet)
OP0181- What are the best drugs to treat D2T RA? In this cohort of 185 pts, switching biologic or JAKi improved disease activity & was considered to be effective for patients with D2TRA, regardless of mode of action @RheumNow #EULAR2024

Mrinalini Dey DrMiniDey ( View Tweet)

10 baseline predictors for achieving treatment response to Secukinumab in the EuroSpA study. Having non-radiographic disease was a negative predictor of obtaining LDA at 6 months and remaining on treatment at 12 months in European axSpA patients initiating secukinumab.… https://t.co/HrRnoDzSPP https://t.co/Gp1KZmPych

Links:

Dr. Antoni Chan synovialjoints ( View Tweet)
How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×